The treatment of STZ/HFD mice with the ALT-100 antibody reduced NASH severity, as evidenced by the reduction in steatosis score, hepatic triglyceride levels, and NAFLD activity score in mice (P < 0.05). In addition, eNAMPT neutralization by ALT-100 also decreased plasma TNF-α levels and hepatic Snail expression in the same animals (P < 0.05). This evidence concerns the gene SNAI1 and metabolic dysfunction-associated steatohepatitis.